C12N 2760/10033
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/10033 (Use of viral protein as therapeutic agent other than vaccine) appears on 5 US grants and 8 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 8
- Assignees
- 4
- Inventors
- 18
- Latest grant
- 9 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 2 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
By publication year.
Recent patents
- Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties9 Sep 2025US 12,409,217 B2Abalos Therapeutics GmbH
- Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV)31 Oct 2023US 11,801,294 B2Abalos Therapeutics GmbH
- LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors8 May 2018US 9,963,718 B2Viratherapeutics GmbH
- LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors16 May 2017US 9,650,649 B2Viratherapeutics GmbH
- Arenavirus inhibiting peptides and uses therefor7 Apr 2015US 8,999,925 B2The Administrators of the Tulane Educational Fund
- Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (im-proved) tumor-regression properties1 Aug 2024US 2024/0252611 A1Abalos Therapeutics GmbH
- Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (im-proved) tumor-regression properties23 May 2019US 2019/0151436 A1Abalos Therapeutics GmbH
- Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (improved) tumor-regression properties.3 May 2018US 2018/0117137 A1
- LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating Virus-Producing Cells for the Therapy of Tumors27 Jul 2017US 2017/0211096 A1Viratherapeutics GmbH
- Soluble and membrane-anchored forms of lassa virus subunit proteins25 Dec 2014US 2014/0377740 A1Biofactura, Inc.
Most cited
By later US patents